Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | ROS1 | P08922 | 1/20 | 0.37 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748333 | 0.92 | HTR6 (0.75) | HTR6EGFRALKZAP70STAT3 | |
| Hydrochloric Acid SCHEMBL1748461 | 0.91 | HTR6 (0.74) | HTR6EGFRALKZAP70STAT3 | |
| SCHEMBL5021168 | 0.87 | HTR6 (0.68) | HTR6EGFRALKZAP70INSR | |
| SCHEMBL5021173 | 0.86 | HTR6 (0.61) | HTR6EGFRALKZAP70INSR | |
| SCHEMBL1748198 | 0.81 | HTR6 (0.50) | HTR6EGFRALKZAP70SOS1 | |
| SCHEMBL1748378 | 0.78 | HTR6 (0.73) | HTR6EGFRALKZAP70INSR | |
| SCHEMBL1748376 | 0.78 | HTR6 (0.73) | HTR6EGFRALKZAP70INSR | |
| SCHEMBL1748377 | 0.78 | HTR6 (0.73) | HTR6EGFRALKZAP70INSR | |
| SCHEMBL5053728 | 0.78 | HTR6 (0.73) | HTR6EGFRALKZAP70INSR | |
| SCHEMBL1748393 | 0.78 | HTR6 (0.82) | HTR6EGFRALKZAP70INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | HTR6 1/4885EGFR 485/4885ALK 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.